Hidradenitis suppurativa is a chronic, inflammatory, and often painful skin disease that causes recurring boil-like lumps that may burst into open wounds and cause irreversible scarring, often in the most intimate parts of the body. There are only a few treatment options available for this disease, such as AbbVie's Humira and Novartis' Cosentyx, which affect approximately 1 in 100 people. However, these treatments often offer insufficient relief.
The stock we are bringing to your attention today is that of Avalo Therapeutics Inc. (AVTX), a clinical-stage biotechnology company developing a drug for hidradenitis suppurativa.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com